breast cancer cells

[Cell Death & Disease] USP35 promoted the growth of ER+ breast cancer in vitro and in vivo, and reduced the sensitivity of ER+ breast cancer cells to endocrine therapies such as tamoxifen and fulvestrant.

[Cancer Cell International] Scientists explain the possible mechanism of the Hippo pathway in combating endocrine resistance, and conclude by recommending endocrine therapy in combination with therapies targeting the Hippo pathway in the study of endocrine-resistant breast cancers.

[Laboratory Investigation] Using a previously established model of in vitro mineralization, the MDA-MB-231 human breast cancer cell line was induced using two osteogenic agents, inorganic phosphate and β-glycerophosphate, and direct monitoring of the mineralization process was conducted using Raman micro-spectroscopy.

[Cell Death Discovery] Through investigating cellular functions including cell proliferation and stem cell features, it was demonstrated that hypoxic cancer-associated fibroblasts exosomes transferred circHIF1A into breast cancer cells, which played an important role in cancer stem cell properties sponging miR-580-5p by regulating CD44 expression.

[Biomedicine & Pharmacotherapy] A library of 17 C1-single and C1/C20-double modified salinomycin analogs was screened to identify compounds with improved activity against breast cancer stem cells.

[Cancer Research] Researchers explored whether the microbiome of the gut and mammary gland mediates the dietary effects on breast cancer. In vitro models of the normal breast epithelium showed that lipopolysaccharide disrupted tight junctions and compromised epithelial permeability.